Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue from product sales	$ 12	$ 113
Collaboration revenue	4	81
Total revenue	16	194
Cost of product sales	17	144
Cost of collaboration revenue	1	3
Total cost of revenue	18	147
Gross (loss) profit	(2)	47
Research and development expense	2,602	2,246
Selling, general and administrative expense	2,740	2,924
Operating loss	(6,668)	(6,864)
Other income (expense):
Warrant revaluation income (expense)	5,257	(1,663)
Interest income	4	2
Loss before income taxes	(1,407)	(8,525)
Income tax benefit	0	0
Net loss	$ (1,407)	$ (8,525)
Per Share Information:
Basic net loss (usd per share)	$ (0.03)	$ (0.21)
Diluted net loss (usd per share)	$ (0.08)	$ (0.21)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding, shares	43,898,785	40,861,329
Diluted weighted average number of common shares outstanding, shares	43,970,853	40,861,329
Affiliated Entity
Research and development expense	$ 1,324	$ 1,741